510(k) device
Smileyscope System (Therapy Mode)
Smileyscope Holding, Inc. · Virtual Reality Behavioral Therapy Device For Pain Relief (QRA, Class II) · First FDA decision Sep 25, 2023, newest Sep 25, 2023Chronic pain
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
2
Naming "Smileyscope"
MAUDE reports
0
Brand "Smileyscope", since 2015
PubMed studies
2
Mentioning "Smileyscope"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Smileyscope System (Therapy Mode)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
K230825 · Decided Sep 25, 2023 · 185 days after receipt
Device type: Virtual Reality Behavioral Therapy Device For Pain Relief (QRA) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Intensive Behavioral Therapy for ObesityNational analysisReview closedCAG-00423NUpdated Sep 18, 2026
- Intensive Behavioral Therapy for Cardiovascular DiseaseNational analysisReview closedCAG-00424NUpdated Sep 18, 2026
- Intensive Behavioral Therapy for ObesityNational determinationOn the books210.12Updated Dec 2, 2024
- Intensive Behavioral Therapy for Cardiovascular DiseaseNational determinationOn the books210.11Updated Dec 2, 2024
Clinical trials
Device studies on ClinicalTrials.gov that name "Smileyscope", any status and sponsor, newest update first.
- Virtual Reality Technology for Vasectomy Pain ModulationPivotal-lookingTerminated
University of MiamiAcademic, hospital or other
NCT05591274 · 120 participants · Start Nov 17, 2022 · Primary completion Mar 28, 2024
Device: SmileyScope Virtual Reality Headset · For: Vasectomy; Pain, Postoperative; Anxiety Postoperative
Sites: Miami, Florida
University of MiamiAcademic, hospital or other
NCT05928910 · 0 participants · Start Jan 30, 2024 · Primary completion Nov 30, 2025
Device: SmileyScope VR · For: Overactive Bladder
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Smileyscope", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QRA
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Smileyscope"[tiab]. The summary above synthesizes these.
- Anxiety-Free Public Dentistry for Adults With Disabilities by Using Head-Mounted Virtual Reality Technology: Protocol for a Feasibility Mixed Methods Study.
Bui DT, McAlinden F, Urban A, et al. · JMIR Res Protoc · 2026Research Support, Non-U.S. Gov't
- Acceptability and Usability of Smileyscope Virtual Reality for Paediatric Pain Management During Burn Procedures: Perspectives of Patients, Carers and Clinicians.
Storey K, Dimanopoulos TA, Plummer K, et al. · J Adv Nurs · 2025
Other devices of this type
Also filed under product code QRA.
- VrntCognifisense, Inc. · 510(k) 2026
- RelieVRx (Pico G3)Appliedvr · 510(k) 2025
- EaseVRxAppliedvr, Inc. · De Novo 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.